PRGN-2013

PRGN-2013 is an investigational **AdenoVerse immunotherapy** developed by Precigen for **chronic hepatitis B virus infection**. Public company disclosures describe it as a **non-replicating gorilla adenovector-based immunotherapy** incorporating a **novel HBV antigen design** intended to generate broad, durable **HBV-specific cytotoxic T-cell responses** against infected cells. The program appears to have remained **preclinical/IND-enabling** and is not listed on Precigen's current pipeline, while third-party pipeline databases characterize it as discontinued, suggesting the asset is no longer an active clinical development priority.